UChicago Medicine China Forum 2019 - Innovations in Cancer Treatment

3:00–6:30 pm
University of Chicago Center in Beijing
20th Floor, Culture Plaza
59A Zhong Guan Cun Street
Haidian District, Beijing

May
17

We cordially invite you to UChicago Medicine China Forum 2019 on May 17th. Throughout the forum, we are going to introduce recent updates and clinical innovation from UChicago Medicine.

One of the centers of clinical excellence at UChicago Medicine is Blood Cancer Programs. UChicago Medicine offers the most advanced care for blood cancers. Especially, we care for more than 300 patients with leukemia, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) each year, making our program one of the largest in the US.

We are also the leader in cellular therapy research and clinical care. Two types of cellular therapy — stem cell transplants and CAR T-cell therapy — were first tested in clinical trials. We participated — and were leaders — in these trials, being among the first to bring these breakthrough approaches to our patients.

At this forum, world-renowned oncologists for blood cancer, Dr. Michael Bishop and Dr. Hongtao Liu, will present new research and clinical updates in leukemia and cellular therapies from UChicago Medicine.

我们诚挚地邀请您参加将于5月17日在芝加哥大学北京中心举办的芝加哥大学医学中心2019年中国论坛。活动中,我们将分享芝大医学中心的近况和临床创新成果。

芝加哥大学医学中心最享有盛誉的临床医学项目之一是血癌的治疗。我们每年收治300多名白血病、骨髓增生异常综合征(MDS)和骨髓增生性肿瘤(MPN)患者,芝大医学中心提供最先进的治疗,是美国最大的同类项目之一。

我们在细胞疗法研究和临床应用领域也处于领先地位。两种细胞疗法——干细胞移植和CAR T细胞疗法最先进入临床试验阶段。我们不仅参与、而且引领这些临床试验,在美国率先将此类划时代的治疗方法用于患者。

本次论坛中,迈克尔·毕晓普和刘洪涛两位世界知名的血癌肿瘤专家将报告芝加哥大学医学中心在白血病和细胞疗法方面最新的科研和临床实践成果。

Language: English, simultaneous translation will be provided.

会议语言:英语,提供中英同传

 

Agenda| 议程

15:00-15:30          Registration

                     注册

15:30-15:35          Welcome Remarks

                     欢迎辞

                     Dr. Mark Wen

                     Executive, Global Business Development / China & Asia

                     International Programs 

                     The University of Chicago Medicine

                     温志刚 博士

                     芝加哥大学医学中心国际业务总监

15:35-16:00          Keynote 1: UChicago Medicine Updates

                     主旨报告1:芝加哥大学医学部近况介绍

                     Dr. Cheng-Kai Kao

                     Section of Hospital Medicine

                     Assistant Professor of Medicine

                     Associate Chief Medical Information Officer

                     Medical Director, Office of International Programs

                     The University of Chicago Medicine

                     高承楷 医生

                     芝加哥大学医学中心助理教授

                     医学信息副主任

                     国际医疗中心医疗总监

16:00-16:15          Q&A 问答

16:15-17:15           Keynote 2: Innovations in Cancer Treatment at UChicago Medicine

                     主旨报告2:芝加哥大学在癌症治疗领域的创新

                     Cellular Therapies 细胞疗法

                     Dr. Michael Bishop
                     Section of Hematology and Oncology

                     Professor of Medicine

                     Director, Hematopoietic Stem Cell Transplantation Program

                     The University of Chicago Medicine

                     迈克尔·毕晓普 医生

                     芝加哥大学医学中心血液肿瘤科教授

                     血液干细胞移植项目主任

 

                     Treatment for Leukemia白血病的治疗

                     Dr. Hongtao Liu

                     Assistant Professor of Medicine

                     Associate-director of Apheresis Service

                     Section of Hematology/Oncology

                     Department of Medicine

                     The University of Chicago Medical Center

                     刘红涛 医生

                     芝加哥大学医学中心血液肿瘤科助理教授

                     血浆分离置换服务副主任

17:15-17:30          Q&A 问答

17:30-18:30          Networking Reception招待会

 

Speakers Bio:

Michael R. Bishop, MD, specializes in the diagnosis and treatment of lymphomas and leukemias. In particular, he cares for patients with hematologic malignancies that have not responded to first-line treatments. An expert in hematopoietic stem cell transplantation (bone marrow transplantation) and cellular therapy, Dr. Bishop and his team are working to address the unique social, economic, physiological and biological issues that patients face while undergoing this treatment.

 

Dr. Bishop's research focuses on the prevention and treatment of relapse after stem cell transplantation. Relapse is the primary cause of treatment failure and death after stem cell transplantation. He has served as the primary investigator on studies designed to prevent and treat disease recurrence after transplantation. Specifically, he works on ways to enhance immune effects of the transplanted cells against cancer.

 

An active contributor to medical literature, Dr. Bishop has authored more than 150 peer-reviewed articles, in addition to more than 30 book chapters and two books on cancer treatment and research. He also serves on the editorial board of numerous scientific journals, including Biology of Blood and Marrow Transplantation.

Dr. Bishop is a dedicated mentor, teaching residents and fellows in classroom, clinical and research settings. Many of his past trainees hold leadership roles in medical oncology and immunology at academic medical centers or at the National Cancer Institute in Bethesda, Maryland.

Since 2001, Dr. Bishop has consistently been named one of the "Best Doctors in America" by Best Doctors, Inc. He previously served as a senior investigator and as the clinical head of stem cell transplantation for the National Cancer Institute at the National Institutes of Health.

 

Cheng-Kai Kao, MD, is an academic hospitalist board-certified in clinical informatics. In addition to clinical practice and residency education, his areas of interest in informatics include clinical decision support, mobile health, data analytics, and healthcare innovation. As associate chief medical information officer, he leads multiple initiatives that leverage information technology to provide decision support for the frontline clinicians to ensure patient safety, optimize clinical workflow to increase work efficiency, enhance usability of the electronic health record system to reduce screen time, and make innovations to improve care quality and patient experience. He is the instructor at Pritzker School of Medicine and Graham School master program of biomedical informatics for clinical decision support systems and healthcare innovation and entrepreneurship courses in University of Chicago.

Dr. Kao also serves as the medical director in the office of international programs. He oversees the clinical course of international patients from all over the world, optimizes their care quality and patient experience, promotes the knowledge transfer service, and fosters collaboration with overseas academic medical centers and healthcare organizations.

Dr. Kao is also the site principal investigator of several phase III clinical trials on novel oral anticoagulants, one of which led to the FDA approval of the new oral anticoagulant Betrixaban. Dr. Kao is named Top Hospitalist by American College of Physicians Hospitalist magazine in 2017.

 

Hongtao Liu, MD, PhD, is a hematologist and medical oncologist, specializing in the diagnosis and treatment of leukemia, stem cell transplantation and cellular therapy. Dr. Liu is currently assistant professor of medicine at University of Chicago. He received MD and Ph.D in immunology from Beijing Medical University, he finished his hematology/oncology fellowship training at University of Chicago. In addition to his clinical role, Dr. Liu is an active researcher. He aims to develop immunotherapy to eliminate minimal residual diseases after chemotherapy or stem cell transplant to fight cancer cells and prevent disease relapse. Dr. Liu has received funding for his work from prominent organizations, including the American Cancer Society, Cancer Research Foundation, and K12 Paul Calabresi Career Development in Clinical Oncology Award. He has been the principal investigator for several investigator-initiated clinical trials focusing on immunotherapy and maintenance therapy to prevent disease relapse in acute leukemia after chemotherapy and stem cell transplantation. He is the national PI of the NCI 9706 REMAIN trial to use PD1 antibody, nivolumab, as maintenance treatment to prevent disease relapse in patients with AML. He participated and took care of patients on the commercial CART treatments and on the CART clinical trials in the treatment of patients with ALL, NHL and MM. He is a member of ASH, ASCO, ASBMT and CAHON.

 

Mark Wen, Ph.D. has been working in the global health and international medical services since 1993.  He worked at Stanford University Medical Center, as Executive Director of Global Health and International Medical Services.  He worked at Virginia Mason Medical Center of Seattle, as director of multi-culture services and created its first international clinic providing culturally sensitive patient care to Seattle region Asian community and patients from Asian countries. 

Recently, Mark worked at Seattle Children Hospital as Vice President and Managing Director of global business development and International Medical Services for three and half years. 

Mark has been very active in many US-China medical exchange programs and well connected with Chinese healthcare industries, Chinese top hospitals and medical schools.  He has managed several leading US hospitals international partnership development both with China and with hospitals in the Mid-east countries. 

Dr. Wen was educated both in China and in the US.  He has an electrical engineering degree from Harbin Institute of Technology, (HIT), Harbin, China.  He received his MBA from Gonzaga University in Spokane, WA, and a doctoral degree from California Pacific University. 

Mark is very active in US-China trade and business development. He has been serving as the president of WA State China Chamber of Commerce for the past 6 years.